Objective: Persistent difficulty in using the upper limb remains a major contributor to physical disability post-stroke. There is a nihilistic view about what clinically relevant changes are possible after the early post-stroke phase. The Queen Square Upper Limb Neurorehabilitation programme delivers high quality, high dose, high intensity upper limb neurorehabilitation during a 3-week (90 hour) programme. Here, we report clinical changes made by the chronic stroke patients treated on the programme, factors that might predict responsiveness to therapy, and the relationship between changes in impairment and activity.
and persistent difficulty in using the upper limb is a major contributor to ongoing physical disability 2 . The general consensus remains that most spontaneous recovery of the upper limb occurs over the first three months after stroke and current levels of rehabilitation result in little improvement after that, particularly at the level of impairment 3 . Improving outcomes through higher dose (time in rehabilitation or number of repetitions) and intensity (dose per session) of rehabilitation is an attractive option 4 . However, clinical trials of higher dose upper limb rehabilitation have generally not produced the magnitude of improvement that will change clinical practice 5 , whether delivered in the early 6 or chronic stages post-stroke [7] [8] [9] . A common factor in these trials is that the dose (in hours) of additional therapy remained relatively low (18-36 hours) . Despite scepticism that stroke patients could tolerate much higher doses 8 , one study managed to deliverer 300 hours of upper limb therapy to chronic stroke patients over 12 weeks and reported changes in measures of both impairment and activity that were far greater than those in lower dose studies 10 . Three hundred hours represents an order of magnitude higher than any dose of rehabilitation offered in previous upper limb rehabilitation trials and deserves further consideration. However, this idea is challenging because of the logistics of setting up such a trial in health care settings where the ethic of high dose, high intensity rehabilitation is not supported. In this context, it is important to report the findings of clinical services that are able to deliver higher doses than conventionally seen. The Queen Square Upper Limb (QSUL) Neurorehabilitation programme is a single centre clinical service that provides 90 hours of timetabled treatment focusing on the post-stroke upper limb in chronic (> 6 months post-stroke) stroke patients. Here we report (i) outcomes for patients admitted to this programme at the National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Trust (UCLH), including 6 month follow up data to look at whether any clinical benefits were maintained, (ii) the characteristics of the patients admitted and any predictors of response and (iii) the relationship between changes in impairment and activity.
METHODS

Participants
Patients were referred by primary care physicians for advice about ongoing management of the paretic upper limb following stroke. There were no criteria around time since stroke. Clinical criteria warranting admission to the programme were broad but were focused on whether we felt able to help patients achieve their goals for the affected upper limb. Barriers to admission included factors precluding the ability to work in l upper limb tasks; (i) absent movements, throughout the limb; (ii) a painful shoulder limiting an active forward reach (mostly due to adhesive capsulitis); (iii) severe spasticity or non-neural loss of range; (iv) unstable medical conditions. These patients were not offered admission to the treatment programme, but were provided with appropriate advice or referred for other treatment approaches. Re-referral to the programme was then considered (for example after successful management of adhesive capsulitis of the shoulder). Features that were more likely to result in admission to the programme included at least some ability to flex the shoulder and at least visible flickers of movement in finger and/or wrist extensors, although this was not always the case as reflected in baseline upper limb scores. Patients were admitted to the programme as day attenders, either from home or from the UCLH dedicated patient accommodation and as such were either self-caring, or self-caring with the support of one other person.
Interventions
Initial assessment consisted of analysis of both movement and performance in activities of daily living.
Subsequent treatment was aimed at reducing impairment and promoting re-education of motor control within activities of daily living. Individualised meaningful tasks were practiced repeatedly in order to facilitate task mastery with a focus on quality of movement. This was achieved through (i) adaptation of the task, e.g. decomposing tasks into individual components to be practiced; (ii) adaptation of the environment, e.g. fabrication of functional splints and adaptation of tools such as cutlery or screwdrivers, to enable integration of the affected hand in meaningful activities; (iii) assistance, e.g. de-weighting the arm to allow strengthening and training of movement quality and control through increased range; (iv) independent task practice. Coaching was considered a key component of the programme, used throughout to embed new skills and knowledge into individual daily routines. Consequently, individuals increase participation and confidence in their desired goals, enhancing self-efficacy and motivation to sustain behavioural change beyond the end of the active treatment period.
This overall approach was achieved through two daily sessions each of physiotherapy and occupational therapy, supplemented with tailored, individualized interventions, including repetitive practice with a rehabilitation assistant or robotic device, sensory retraining, use of dynamic and functional orthoses, neuromuscular electrical stimulation, and group work. Furthermore, patients were encouraged to work on cardiovascular fitness during the programme. A 6 hour timetable was implemented 5 days a week for 3 weeks (total therapy time, 90 hours). Motor tasks could be described as passive or active, assisted or unassisted, functional or non-functional. Over the three weeks, the aim was to increase the time spent on active, unsupported functional tasks, depending on a patient's level of impairment and progress. The programme was staffed with a 1:1 staff to patient ratio (2 physiotherapists, 2 occupational therapists, 2 rehabilitation assistants for 6 patients). 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 and sensation (as indexed by light touch on palm as described in Fugl-Meyer assessment of the upper extremity).
The affected upper limb was assessed on admission (T1), discharge (T2), 6 weeks (T3) and 6 months (T4) post-discharge, using the following measures: Fugl-Meyer (upper limb) (FM-UL), Action Research Arm Test (ARAT), Chedoke Arm and Hand Activity Inventory (CAHAI-13), Arm Activity Measure
The FM-UL is a stroke-specific, performance-based impairment index (where impairment refers to loss of body structure and function) with good validity and intra-and inter-rater reliability 11, 12 . Here we have used a modified version of the FM-UL, excluding measures of co-ordination and reflexes based on hierarchical properties of the scale 13 , and as these do not relate to the upper limb synergies of interest 14 . The minimum clinically important difference (MCID) has been reported as 5.25 points 15 .
The ARAT assesses a patient's ability to handle objects differing in size, weight and shape and therefore can be considered to be an arm-specific measure of activity limitation 16 . The MCID has been suggested as 5.7 points 17 .
The CAHAI-13 is a validated, upper-limb measure that uses a 13-point quantitative scale in order to assess recovery of the arm and hand in performing activities of daily living after a stroke 18 . It is a performance test using day to day items. It is not designed to measure the patient's ability to complete the task using only their unaffected hand, but rather to encourage bilateral upper limb use. No MCID has been reported for CAHAI-13 (although the minimum detectable change is reported as 6.2 18 ).
The Arm Activity Measure (ArmA) is a patient reported outcome score 19 with two components. The ArmA-A asks patients about their ability to care for their affected arm either themselves with their unaffected arm or by a carer or a combination of both of these. ArmA-B asks patients about how easy or hard it is to use the affected arm in activities of daily living. For ArmA-A and ArmA-B, note that lower scores are better.
No MCID has been reported for ArmA-A or ArmA-B.
Analysis plan
Our primary aim was to measure changes in upper limb deficit over time were examined using the Friedman test for all outcome scores. Post-hoc analysis to test differences between individual time points was carried out with the Wilcoxon signed-ranks test. As a secondary aim, we were then interested in whether baseline characteristics correlated with final (T4) outcomes. We initially examined for correlations between individual baseline characteristics and outcomes using Spearman's rank correlation. We also tested whether median T4 outcomes were different depending on gender or side of lesion using Wilcoxon rank indication that time since stroke has a linear effect on outcome. Lastly we performed multiple linear regression to look for predictors of either absolute scores at T4 or the change in scores T1 to T4. Lastly, we also examined the relationship between the changes in outcome scores from admission to 6 month follow up using Spearman's rank correlation.
RESULTS
Baseline characteristics
Between January 2015 and December 2017, 268 patients were admitted to the QSUL programme (representing 46% of patients assessed in out-patient clinic). 40.4% of patients were admitted from home, whilst 59.6% stayed in the UCLH dedicated patient accommodation. Note, only 16 patients were admitted to the programme prior to 6 months post-stroke, and only 1 prior to 3 months, reflecting overall referral patterns to the programme.
Of those, 30 were non-stroke (12 traumatic brain injury, 8 brain tumour, 3 peripheral neurological conditions, 3 spinal cord injury, 4 inflammatory central nervous system conditions) and are excluded from this analysis. A total of 238 stroke patients were admitted, of whom 224 completed follow up assessments at 6 weeks and 6 months after discharge from the programme. Of the 14 incomplete follow ups, 5 patients considered it too far to travel for follow up, 4 patients suffered intercurrent illness (recurrent stroke, fractured hip, complications of surgery, seizures), and 5 could not be contacted. Differences in median values between complete and missing data groups was tested with Wilcoxon Signed Rank test. Where appropriate, differences in proportions between complete and missing data groups were tested with Chisquared test. There were no differences in baseline characteristics between patients who completed follow up and those who were lost to follow up (table 1). Because (i) there was no systematic difference between subjects with complete data and those with missing data, and (ii) only outcome data (not explanatory variables, which were collected at T1) were missing, then missing data were dealt with by performing a complete case analysis (i.e. only using subjects where complete data were available).
Changes in upper limb deficit
The median scores for the affected upper limb at admission (T1), discharge (T2), 6 weeks (T3) and 6 months post-discharge (T4) are shown in table 2. The Friedman test was used to demonstrate a significant effect of (T1-T2, T1-T3, T1-T4, T2-T3, T2-T4, T3-T4) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
7 whose median is zero (i.e. testing whether the change in score is significantly greater than zero). A Bonferroni correction was applied to the significance level for the 6 comparisons made for each of the 5 different outcome scores (p<0.05/30 = 0.0017). For each outcome score, there was a significant difference between each pair of time points compared, except T2-T3 for the ArmA-A (table S1) 
Predictors of outcome
Firstly, we were interested to see whether any baseline characteristics (T1) correlated with final outcome at T4. Spearman's rank correlation was used to show that admission values at T1 for FM-UL, ARAT, CAHAI, ArmA-A, ArmA-B all correlated with T4 values for FM-UL, ARAT, CAHAI, ArmA-A, ArmA-B. In addition, admission BI correlated with T4 CAHAI; admission mRS correlated with T4 FM-UL, ARAT and CAHAI; admission sensation correlated with T4 CAHAI. Age, NFI and HADS at T1 did not correlate with any scores at T4. All p-values were corrected for multiple comparisons by Bonferroni correction (Table 4 ). Figure 3 helps to visualise the influence of baseline admission scores on final score at 6 month follow up.
Furthermore, a Wilcoxon ranked sum test showed that T4 outcomes did not differ by gender or affected hemisphere. There was a trend for patients with non-dominant affected limbs to achieve better (lower)
ArmA-B scores in comparison to those with dominant affected limbs (median 17 for non-dominant vs -27 for dominant, p = 0.027, uncorrected). There were no differences in T4 scores between patients with dominant or non-dominant affected limbs for any of the other outcome scores.
Secondly, we were interested to see whether any baseline characteristics (T1) correlated with magnitude of change from admission to 6 months follow up (T1 to T4). Spearman's rank correlation was used to show that FM-UL, ARAT, CAHAI and ArmA-B at T1 correlated with change in ARAT and CAHAI (but not FM-UL) from T1 to T4. FM-UL at T1 also correlated with change in ArmA-B from T1 to T4. ArmA-A at T1 correlated with change in both CAHAI and ArmA-A from T1 to T4. ArmA-B at T1 correlated with change in both ArmA-A and ArmA-B from T1 to T4. Age, NFI, HADS, BI and mRS at T1 did not correlate with any scores at T4. All pvalues were corrected for multiple comparisons by Bonferroni correction (table 5). We also performed a Wilcoxon ranked sum test to show that change in scores from T1 to T4 were not different depending on gender or affected hemisphere. There was a trend for patients with non-dominant affected limbs to 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
improve on the ArmA-B between T1 and T4 to a greater degree than those with dominant affected limbs (median changes of -17.5 for non-dominant vs -12 for dominant, p = 0.017, uncorrected). There were no differences in change scores between patients with dominant or non-dominant affected limbs for any of the other outcome scores.
We then performed multiple linear regression to look for predictors of either absolute scores at 6 months after treatment (T4) or the change in scores from admission to 6 months after treatment (T1 to T4) using age, BI, mRS, NFI, HADS and sensation on admission together with the matching initial score on admission (e.g. FM1 if attempting to predict FM4 or change from FM1 to FM4). Models predicting T4 scores for FM-UL, ARAT, CAHAI, ArmA-A and ArmA-B were all highly significant (p<0.0001). Models predicting change from T1 to T4 for ARAT, CAHAI, ArmA-A and ArmA-B (but not FM-UL) were also highly significant (p<0.0001).
However, the only factor that significantly contributed to these models was the matched initial score on admission (e.g. ARAT at T1 predicting ARAT at T4), but not age, BI, mRS, NFI, HADS or sensation on admission. As such, this approach did not contribute further to the correlation results shown in table 4 and 5, with regression models not able to account for a higher proportion of variance in scores at T4 or change in scores from T1 to T4 than the admission score (see also Figure 3 ).
Relationship between outcome measures
Each outcome score assesses a different aspect of recovery. Using Spearman's rank correlation, we examined the relationship between the changes in outcome scores from admission to 6 month follow up.
A Bonferroni correction was applied to the significance level for the 10 comparisons made between the 5 different outcome scores (p<0.05/10 = 0.005) ( Table 6 and Figure 4 ). Changes in FM-UL, ARAT and CAHAI correlated weakly with one another. The ArmA-B change correlated with changes in both ArmA-A and ARAT.
DISCUSSION
We report the results from a single centre clinical service delivering high dose and intensity of upper limb focused neurorehabilitation for people with stroke. Almost all of these patients were in the chronic (>6 months after stroke) phase. The key messages from our results are (i) patients were able to complete the 90 hours of the programme, despite exhibiting a range of impairments and fatigue levels, (ii) large clinical improvements in upper limb impairment (FM-UL) and activity (ARAT, CAHAI, ArmA) were observed, and (iii) these changes were maintained, or even improved upon, 6 months after treatment.
The QSUL programme is based on the hypothesis that a high dose and intensity of upper limb neurorehabilitation can lead to large clinically meaningful improvements in chronic stroke patients. It is worth comparing the magnitude of the changes with previous reported clinical trials of upper limb 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Importantly, we report that these group level effects continued to improve at 6 weeks and then 6 months after treatment had stopped, ( figure 1 and 2) . comparison with other studies is difficult because some may have been conducted in less severely affected patients, the dose (measured in time) of the intervention may have been lower, and the numbers of patients enrolled has been much lower than we report here. Whilst this report of our single-centre clinical outcomes is not a replication of the McCabe study, it suggests that the next wave of upper limb rehabilitation trials must investigate much higher doses of the treatment than is currently attempted.
Whilst we will hear the refrain that it is not possible to deliver such high doses in current health care settings (the pragmatic view), it is in fact precisely the role of clinical research to challenge what we currently do in order to reshape and improve our clinical services to make them better (the aspirational view). Those involved in stroke medicine will recognise that this is exactly the effect that thrombolysis had on acute management of stroke, leading to the high quality hyperacute stroke services we see today. Post-stroke neurorehabilitation must adopt the same aspirational approach 20 .
Whilst the appropriate dose of upper limb rehabilitation is debated, the content of the intervention receives less attention. Our approach was based on analysis of movement and performance in activities of daily living, reduction of impairment and re-education of quality and control of movement within activities of daily living, all performed in an iterative and non-linear fashion. Education, self-efficacy and goal setting were integral components of the programme, and we can speculate that the education and focus on selfefficacy contributed to the continued increase in scores after treatment stopped. The therapeutic approach taken towards specific impairments was the same across patients, but approaches at the activity and participation level will necessarily vary as they are tailored to an individual's specific meaningful goals. We acknowledge that an immediate challenge for us and for the field in general is to be able to define what the 'active ingredients' of neurorehabilitation are, so that these elements can be further tested. Our approach appears to have similarities with that taken by McCabe et al, with an emphasis on the quality of 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 10 the movement as well as the final goal of the movement. The latter is often the sole focus of task-specific repetition, which has been used in many upper limb rehabilitation studies to date. The evidence for repetitive task-specific training is of low to moderate quality 21 and the effects have been disappointingly small even when the number of repetitions has been greatly increased 8 . It is difficult to tell whether this lack of effect is specific to task-specific training, because in general the dose (in terms of hours of active training) has been quite low, whether delivered by a therapist 21 or robotic device 22 . There have been suggestions that chronic stroke patients might not tolerate more training than has been offered in these trials 8 , but the study of McCabe et al 10 and now our own clinical experience undermine this view.
Although this result is exciting, we must acknowledge that it is a single centre clinical service with no randomisation and no control group. Although there are some reports of late improvement up to 12 months after lacunar stroke 23 , we expect that chronic stroke patients who are often several years after their stroke, will not change across this range of outcome scores without treatment. We suggest that it is unlikely that this magnitude of change would be seen without therapeutic intervention, but this assertion requires empirical confirmation. Our work however, provides strong justification for undertaking such high dose clinical trials. Clinic data on which to base these future studies is sorely lacking and this has led to the proliferation of low dose pragmatic rehabilitation studies. However, there is still much to be learned from published data arising from clinical services in neurorehabilitation 24 , making up for lack of clinical trial rigour with large sample sizes that are rarely achieved in clinical trials. Data from clinical services therefore have the potential to refine what experimental questions are addressed in future randomised clinical trials.
Another limitation is the unblinded nature of the assessments, introducing possible bias into the results.
All assessors are also therapists on the programme, although we ensure that assessments are carried out by therapists from another team who are not treating the patient. Fidelity of outcome scores is always an important issue in clinical trials. In our programme, we have instituted regular in-service training for FM-UL, ARAT and CAHAI to ensure high levels of reproducibility between assessors.
A common complaint regarding single centre clinical services is that they select only patients most likely to succeed. It is important to acknowledge that the QSUL programme does not have strict inclusion/exclusion criteria. Although our patients are generally younger than the average stroke patient and have high levels of independence they have a wide range of upper limb impairments. It can be seen from figures 1 and 2 that the range of severity of the upper limb on the QSUL programme was very broad, quite unlike a clinical trial, although the median scores suggest that patients were weighted towards the moderate-severe end of upper limb impairment and activity limitation. We would argue that the QSUL programme is aspirational in its goals (high quality, high dose, high intensity treatment) and pragmatic in its application (wide range of patients admitted onto the programme). It's interesting to consider the potential impact of initial upper limb severity on our outcomes, but in fact, although initial score correlates well with the final score at 6 (table 4) , the change in score correlates only weakly with initial score (table 5, Figure 3 ). There are two ways this 'mixed-bag' approach may have potentially reduced the overall magnitude of the clinical effects we observed. Firstly, there may be a ceiling effect from patients with relatively high scores on admission. Secondly, many of our patients were quite severely impaired. Indeed, a quarter of our patients had an admission ARAT below 7, which suggests they have great difficulty in using their hand in any kind of activity of daily living. The treatment goals in these type of patients might initially be very different to the moderate to mild type patients, with benefits less likely to be reflected in changes in FM-UL and ARAT compared to the CAHAI or ArMA for example. However, the wide range of patients treated in the programme means that no clear patterns, in relation to differential effects on various scores, could be seen ( Figure 4 ). Some might argue that the wide range of responses, including those patients who changed very little, points to the need for stratification and selection of those patients most likely to respond, and this is certainly a reasonable view. However, the first point to make is that our results show that with large enough numbers and a high enough dose of the intervention, it is possible to demonstrate large group-level effects in relatively unselected populations of chronic stroke patients. Indeed, if the former (stratification) approach is to be adopted, then these kind of large data sets will be required to determine what the characteristics of the 'responders' are likely to be. The second point to make is that we found no strong clinical indicators, amongst our measured explanatory variables, of which patients were most likely to change, including sensory loss in the hand, fatigue 25 and depression (tables 4 and 5). It might be that neurophysiological (presence or absence of motor evoked potentials) 26 , neuroimaging (assessment of corticospinal tract, whole brain damage or brain function) 27-30 or cognitive (sustained attention, memory, motivation) 31, 32 measures are required for accurate stratification based on likely response, and this can certainly be tested in future.
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